Dow forges cancer collaboration

- Last updated on GMT

Related tags: Oncology, Cancer

A collaboration between a Avidex of the UK and Dow Chemical aims to
create a series of new 'biotargeted' radiopharmaceuticals for
cancer treatment.

A collaboration between a small UK biotechnology company and Dow Chemical aims to create a series of new 'biotargeted' radiopharmaceuticals for cancer treatment.

Dow will contribute its ChelaMed chelation technology and radiopharmaceutical services to the collaboration while the UK firm, Avidex, will supply the targeting technology. Avidex has built a position in monoclonal T cell receptors, and Dow's ChelaMed process will be used to attach a radioisotope to a targeted mTCR.

The first effort will focus on Avidex's mTCR product EsoDex for the treatment of lung and bladder cancer. EsoDex targets the NY-ESO antigen, a very specific marker on cancer cells.

Although NY-ESO is a very specific tumour associated antigen, it is expressed mostly inside the cell and therefore would not be detected by a therapeutic monoclonal antibody. EsoDex, from Avidex, however, is designed to specifically bind the fragments of the NY-ESO antigen that are presented on the surface of tumour cells by HLA class I molecules. Using the Dow chelator to attach a radionuclide (such as yttrium-90 or lutetium-177) as a payload to the NY-ESO-specific mTCR will enable targeted delivery of such cytotoxic agents.

Dow's director of pharmaceutical technologies, Mark Cassidy, said: "Biotargeted radiopharmaceuticals can potentially increase therapeutic options, raise effectiveness and reduce side effects to improve quality of life for patients with cancer and other diseases."

Related topics: Preclinical Research, Ingredients

Related news

Follow us

Products

View more

Webinars